Top

Published in:

01-11-2012 | Original Article

Intratumoral delivery of CpG-conjugated anti-MUC1 antibody enhances NK cell anti-tumor activity

Authors: Jorge Schettini, Amritha Kidiyoor, Dahlia M. Besmer, Teresa L. Tinder, Lopamudra Das Roy, Joseph Lustgarten, Sandra J. Gendler, Pinku Mukherjee

Published in: Cancer Immunology, Immunotherapy | Issue 11/2012

Abstract

Monoclonal antibodies (mAbs) against tumor-associated antigens are useful anticancer agents. Antibody-dependent cellular cytotoxicity (ADCC) is one of the major mechanisms responsible for initiating natural killer cell (NK)-mediated killing of tumors. However, the regulation of ADCC via NK cells is poorly understood. We have investigated the cytolytic activity of NK cells against pancreatic cancer cells that were coated with an antibody directed against the human tumor antigen, Mucin-1 designated HMFG-2, either alone or conjugated to CpG oligodeoxynucleotide (CpG ODN). Conjugated antibodies were tested for their ability to elicit ADCC in vitro and in vivo against pancreatic cancer cells. NK cells cultured in the presence of immobilized CpG ODN, HMFG-2 Ab, or CpG ODN-conjugated HMFG-2 Ab were able to up-regulate perforin similarly. Interestingly, a significant higher ADCC was observed when CpG ODN-conjugated HMFG-2-coated tumor cells were co-cultured with NK cells compared to unconjugated HMFG-2 Ab or CpG ODN alone. Moreover, MyD88-deficient NK cells can perform ADCC in vitro. Furthermore, intratumoral injections of CpG ODN-conjugated HMFG-2 induced a significant reduction in tumor burden in vivo in an established model of pancreatic tumor in nude mice compared to CpG ODN or the HMFG-2 alone. Depletion of macrophages or NK cells before treatment confirmed that both cells were required for the anti-tumor response in vivo. Results also suggest that CpG ODN and HMFG-2 Ab could be sensed by NK cells on the mAb-coated tumor cells triggering enhanced ADCC in vitro and in vivo.

Weiner LM, Dhodapkar MV, Ferrone S (2009) Monoclonal antibodies for cancer immunotherapy. Lancet 373(9668):1033–1040PubMedCrossRef

Adams GP, Weiner LM (2005) Monoclonal antibody therapy of cancer. Nat Biotechnol 23(9):1147–1157PubMedCrossRef

Cartron G et al (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99(3):754–758PubMedCrossRef

Weng WK, Levy R (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21(21):3940–3947PubMedCrossRef

Ravetch JV, Bolland S (2001) IgG Fc receptors. Annu Rev Immunol 19:275–290PubMedCrossRef

Clynes RA et al (2000) Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6(4):443–446PubMedCrossRef

Sulica A et al (2001) Ig-binding receptors on human NK cells as effector and regulatory surface molecules. Int Rev Immunol 20(3–4):371–414PubMedCrossRef

Peipp M et al (2008) Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Blood 112(6):2390–2399PubMedCrossRef

Leidi M et al (2009) M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro. J Immunol 182(7):4415–4422PubMedCrossRef

10.

Karagiannis SN et al (2007) IgE-antibody-dependent immunotherapy of solid tumors: cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cells. J Immunol 179(5):2832–2843PubMed

11.

Khan KD et al (2006) A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin’s lymphoma. Clin Cancer Res 12(23):7046–7053PubMedCrossRef

12.

Umana P et al (1999) Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol 17(2):176–180PubMedCrossRef

13.

Orange JS, Ballas ZK (2006) Natural killer cells in human health and disease. Clin Immunol 118(1):1–10PubMedCrossRef

14.

Bowles JA, Weiner GJ (2005) CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells. J Immunol Methods 304(1–2):88–99PubMedCrossRef

15.

Fehniger TA, Caligiuri MA (2001) Interleukin 15: biology and relevance to human disease. Blood 97(1):14–32PubMedCrossRef

16.

Moga E et al (2008) NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma. Exp Hematol 36(1):69–77PubMedCrossRef

17.

Krieg AM (2006) Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 5(6):471–484PubMedCrossRef

18.

Ballas ZK (2007) Modulation of NK cell activity by CpG oligodeoxynucleotides. Immunol Res 39(1–3):15–21PubMedCrossRef

19.

Krieg AM (2002) CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20:709–760PubMedCrossRef

20.

Roda JM, Parihar R, Carson WE III (2005) CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells. J Immunol 175(3):1619–1627PubMed

21.

Krieg AM et al (2004) Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J Immunother 27(6):460–471PubMedCrossRef

22.

Link BK et al (2006) Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. J Immunother 29(5):558–568PubMedCrossRef

23.

Andoniou CE et al (2005) Interaction between conventional dendritic cells and natural killer cells is integral to the activation of effective antiviral immunity. Nat Immunol 6(10):1011–1019PubMedCrossRef

24.

Adachi O et al (1998) Targeted disruption of the MyD88 gene results in loss of IL-1 and IL-18-mediated function. Immunity 9(1):143–150PubMedCrossRef

25.

Tinder TL et al (2008) MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma. J Immunol 181(5):3116–3125PubMed

26.

Mukherjee P et al (2009) Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition. J Immunol 182(1):216–224PubMedCrossRef

27.

Besmer DM et al (2011) Pancreatic ductal adenocarcinoma mice lacking mucin 1 have a profound defect in tumor growth and metastasis. Cancer Res 71(13):4432–4442PubMedCrossRef

28.

Roy LD et al (2011) MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition. Oncogene 30(12):1449–1459PubMedCrossRef

29.

Taylor-Papadimitriou J et al (1981) Monoclonal antibodies to epithelium-specific components of the human milk fat globule membrane: production and reaction with cells in culture. Int J Cancer 28(1):17–21PubMedCrossRef

30.

Grosso JF et al (2004) MUC1/sec-expressing tumors are rejected in vivo by a T cell-dependent mechanism and secrete high levels of CCL2. J Immunol 173(3):1721–1730PubMed

31.

Vitetta ES, Hart DA, Forman J (1978) Relationship between trinitrophenol and H-2 antigens on trinitrophenyl-modified spleen cells. III. Quantitative aspects of trinitrophenol binding on cells treated with trinitrobenzene sulfonic acid. J Immunol 121(3):997–1001PubMed

32.

Trevani AS et al (2003) Bacterial DNA activates human neutrophils by a CpG-independent pathway. Eur J Immunol 33(11):3164–3174PubMedCrossRef

33.

Sfondrini L et al (2002) Prevention of spontaneous mammary adenocarcinoma in HER-2/neu transgenic mice by foreign DNA. FASEB J 16(13):1749–1754PubMedCrossRef

34.

Sharma S et al (2008) Systemic targeting of CpG–ODN to the tumor microenvironment with anti-neu-CpG hybrid molecule and T regulatory cell depletion induces memory responses in BALB-neuT tolerant mice. Cancer Res 68(18):7530–7540PubMedCrossRef

35.

Zafir-Lavie I, Michaeli Y, Reiter Y (2007) Novel antibodies as anticancer agents. Oncogene 26(25):3714–3733PubMedCrossRef

36.

Sanjuan MA et al (2006) CpG-induced tyrosine phosphorylation occurs via a TLR9-independent mechanism and is required for cytokine secretion. J Cell Biol 172(7):1057–1068PubMedCrossRef

37.

Liese J, Schleicher U, Bogdan C (2007) TLR9 signaling is essential for the innate NK cell response in murine cutaneous leishmaniasis. Eur J Immunol 37(12):3424–3434PubMedCrossRef

38.

Krieg AM (2003) CpG motifs: the active ingredient in bacterial extracts? Nat Med 9(7):831–835PubMedCrossRef

39.

Zhu P et al (2009) Mechanism and regulatory function of CpG signaling via scavenger receptor B1 in primary B cells. J Biol Chem 284(34):22878–22887PubMedCrossRef

40.

Trieu A et al (2009) TLR9-independent effects of inhibitory oligonucleotides on macrophage responses to S. typhimurium. Immunol Cell Biol 87(3):218–225PubMedCrossRef

41.

Hokeness-Antonelli KL et al (2007) IFN-alphabeta-mediated inflammatory responses and antiviral defense in liver is TLR9-independent but MyD88-dependent during murine cytomegalovirus infection. J Immunol 179(9):6176–6183PubMed

42.

Rutz M et al (2004) Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner. Eur J Immunol 34(9):2541–2550PubMedCrossRef

43.

Sivori S et al (2006) Comparison of different CpG oligodeoxynucleotide classes for their capability to stimulate human NK cells. Eur J Immunol 36(4):961–967PubMedCrossRef

44.

Lauzon NM, Mian F, Ashkar AA (2007) Toll-like receptors, natural killer cells and innate immunity. Adv Exp Med Biol 598:1–11PubMedCrossRef

Title: Intratumoral delivery of CpG-conjugated anti-MUC1 antibody enhances NK cell anti-tumor activity
Authors: Jorge Schettini
Amritha Kidiyoor
Dahlia M. Besmer
Teresa L. Tinder
Lopamudra Das Roy
Joseph Lustgarten
Sandra J. Gendler
Pinku Mukherjee
Publication date: 01-11-2012
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 11/2012
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-012-1264-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2012

Stratification according to HGG-IMMUNO RPA model predicts outcome in a large group of patients with relapsed malignant glioma treated by adjuvant postoperative dendritic cell vaccination

B7-H3 is expressed in human hepatocellular carcinoma and is associated with tumor aggressiveness and postoperative recurrence

Annexin-V promotes anti-tumor immunity and inhibits neuroblastoma growth in vivo

Pre-clinical assessment of autologous DC-based therapy in ovarian cancer patients with progressive disease

Controlled-rate freezer cryopreservation of highly concentrated peripheral blood mononuclear cells results in higher cell yields and superior autologous T-cell stimulation for dendritic cell-based immunotherapy

DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8+ T-cell responses and increases PSA doubling time

Keynote webinar | Spotlight on antibody–drug conjugates in cancer